Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.82 -2.78 (-9.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗

August 28, 2025

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Via Benzinga

Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch ↗

August 28, 2025

The company has made a name for itself with a drug that treats a progressive kidney condition.

Via Investor's Business Daily

Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 28, 2025

Via Benzinga

Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗

August 28, 2025

Via Benzinga

Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up ↗

August 15, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Preview: Travere Therapeutics ↗

August 05, 2025

Via Benzinga

Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss ↗

August 06, 2025

Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings.

Via Chartmill

Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews ↗

July 01, 2025

Via Benzinga

7 Analysts Assess Travere Therapeutics: What You Need To Know ↗

June 11, 2025

Via Benzinga

Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 16, 2025

Via Benzinga

IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why ↗

May 16, 2025

Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug.

Via Investor's Business Daily

Topics Government

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Travere Therapeutics's Earnings: A Preview ↗

April 30, 2025

Via Benzinga

Analyst Expectations For Travere Therapeutics's Future ↗

February 24, 2025

Via Benzinga

Top movers in Friday's pre-market session ↗

May 16, 2025

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 16, 2025

Via Benzinga

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

May 16, 2025

Via Benzinga

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries ↗

May 16, 2025

Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 15, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

May 15, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth? ↗

May 02, 2025

Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX).

Via Chartmill

Assessing Travere Therapeutics: Insights From 8 Financial Analysts ↗

April 23, 2025

Via Benzinga

Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval ↗

April 03, 2025

The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.

Via Investor's Business Daily

The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts ↗

April 01, 2025

Via Benzinga

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 01, 2025

Via Benzinga

Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug ↗

February 11, 2025

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.

Via Stocktwits

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug ↗

February 11, 2025

The company is nearing a highly anticipated approval for a kidney disease drug.

Via Investor's Business Daily

Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday ↗

February 11, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

Headline News about Travere Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today